XML 70 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2013
FAIR VALUE MEASUREMENTS [Abstract]  
FAIR VALUE MEASUREMENTS

2. FAIR VALUE MEASUREMENTS

     Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Assets and liabilities measured at fair value must be categorized into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation:

Level 1       Unadjusted quoted prices in active markets for identical assets or liabilities;
     
Level 2   Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or
     
Level 3   Unobservable inputs, such as discounted cash flow models or valuations.


     The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement in its entirety.

     As of June 30, 2013 and December 30, 2012, the Company held certain items that were required to be measured at fair value on a recurring basis. These included derivative assets and liabilities and deferred compensation plan assets. Derivative assets and liabilities consist of long and short positions on exchange-traded commodity futures instruments. The Company maintains nonqualified deferred compensation plans for executives and other highly compensated employees. Investments are maintained within a trust and include money market funds, mutual funds and life insurance policies. The cash surrender value of the life insurance policies is invested primarily in mutual funds. The following items were measured at fair value on a recurring basis:

        June 30, 2013
    Level 1       Level 2       Level 3       Total
    (In thousands)
Derivative assets - commodity futures instruments   $      4,506     $      -   $ -   $      4,506  
Derivative assets - commodity options instruments     -       2,165     -     2,165  
Deferred compensation plan assets     7,668       -     -     7,668  
Derivative liabilities - commodity futures instruments     (766 )     -     -     (766 )
 
    December 30, 2012
    Level 1   Level 2   Level 3   Total
    (In thousands)
Derivative assets - commodity futures instruments   $ 1,821     $ -   $      -   $ 1,821  
Deferred compensation plan assets     7,591       -     -     7,591  
Derivative liabilities - commodity futures instruments     (1,530 )     -     -     (1,530 )

     The valuation of financial assets and liabilities classified in Level 1 is determined using a market approach, taking into account current interest rates, creditworthiness, and liquidity risks in relation to current market conditions, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of financial assets and liabilities in Level 2 is determined using a market approach based upon quoted prices for similar assets and liabilities in active markets or other inputs that are observable for substantially the full term of the financial instrument. The valuation of financial assets in Level 3 is determined using an income approach based on unobservable inputs such as discounted cash flow models or valuations.

     In addition to the fair value disclosure requirements related to financial instruments carried at fair value, accounting standards require interim disclosures regarding the fair value of all of the Company's financial instruments. The methods and significant assumptions used to estimate the fair value of financial instruments and any changes in methods or significant assumptions from prior periods are also required to be disclosed. The carrying amounts and estimated fair values of financial assets and liabilities recorded in the Condensed Consolidated Balance Sheets consisted of the following:

        June 30, 2013   December 30, 2012    
    Carrying     Fair     Carrying     Fair     Note
    Amount   Value   Amount   Value   Reference
    (In thousands)    
Derivative assets - commodity futures instruments   $      4,506     $      4,506     $      1,821     $      1,821     5
Derivative assets - commodity options instruments     2,165       2,165       -       -     5
Deferred compensation plan assets     7,668       7,668       7,591       7,591      
Derivative liabilities - commodity futures instruments     (766 )     (766 )     (1,530 )     (1,530 )   5
Long-term debt and other borrowing arrangements     (912,332 )     (961,432 )     (1,164,756 )     (1,208,730 )   8

     Derivative assets were recorded at fair value based on quoted market prices and are included in the line item Prepaid expenses and other current assets on the Condensed Consolidated Balance Sheet. Deferred compensation plan assets were recorded at fair value based on quoted market prices and are included in the line item Other assets in the Condensed Consolidated Balance Sheets. Derivative liabilities were recorded at fair value based on quoted market prices and are included in the line item Accrued expenses and other current liabilities on the Condensed Consolidated Balance Sheet. The fair values of the Company's long-term debt and other borrowing arrangements were estimated by calculating the net present value of future payments for each debt obligation or borrowing by: (i) using a risk-free rate applicable for an instrument with a life similar to the remaining life of each debt obligation or borrowing plus the current estimated credit risk spread for the Company or (ii) using the quoted market price at June 30, 2013 or December 30, 2012, as applicable.

     In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges when required by U.S. GAAP. There were no significant fair value measurement losses recognized for such assets and liabilities in the periods reported.